Guardant Health (NASDAQ: GH) is one of 24 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Guardant Health to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, earnings, analyst recommendations and profitability.
This is a summary of recent ratings and recommmendations for Guardant Health and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Guardant Health Competitors||173||627||736||46||2.41|
This table compares Guardant Health and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Guardant Health Competitors||-105.92%||-115.51%||-34.04%|
Insider and Institutional Ownership
69.6% of Guardant Health shares are owned by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 17.1% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Guardant Health and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Guardant Health||$90.64 million||-$85.06 million||-27.46|
|Guardant Health Competitors||$1.13 billion||$64.24 million||-1.79|
Guardant Health’s competitors have higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Guardant Health Company Profile
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.